All In Biotech

Drug Trial Radar · NCT07577804

A Study to Evaluate the Efficacy and Safety of CHF10196 Tablets (Florensocatib) Compared With Placebo in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis

A Phase III, Randomised, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Treatment With CHF10196 Tablets (Florensocatib) Compared With Placebo for up to 78 Weeks, Followed by an Open-label Extension, in Male and Female Participants 12 to 85 Years of Age With Bronchiectasis

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 904 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

904

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Apr 2030

Study completion Apr 2030

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
May 11, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to find out whether the tablet CHF10196 is safe and effective for people with non-cystic fibrosis bronchiectasis, a long-term lung disease that causes widened airways, mucus buildup, infections, and flare ups of symptoms. The main goal is to see whether CHF10196 can reduce the number of lung flareups each year compared with placebo. The study will also assess whether it can improve lung function, quality of life, and overall safety. The study has two phases. In the first phase, participants receive either CHF10196 tablets or placebo without knowing which one they are taking. In the second phase, all participants receive CHF10196 so its long-term safety can be further studied. Adults aged 18 to 85 years and adolescents aged 12 to under 18 years can take part, while continuing their usual stable bronchiectasis treatment. Up to about 2.5 years of participation are planned. Around 904 participants will be enrolled, with regular clinic visits and phone check ins. In the first phase, participants take either CHF10196 or inactive tablets once daily; in the second phase, everyone takes CHF10196 once daily. Temporary treatment interruptions are allowed if needed, and participants who stop treatment early may still continue study visits, depending on the study phase.

Conditions

  • Bronchiectasis

Interventions

  • CHF10196 tablets (florensocatib)Drug

    40mg tablets taken once daily.

  • PlaceboDrug

    Tablets taken once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The annualised rate of adjudicated pulmonary exacerbationsTime frame: Up to 78 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.